European authorities are warning that vials of Roche's cancer med Herceptin that were stolen in Italy are now showing up across the continent with little or none of its active ingredient.
The U.K. is investing £38 million in its National Biologics Manufacturing Centre, part of the country's "High Value Manufacturing Catapult" effort started several years ago to increase its presence in biologics.
Welcome to the latest edition of our weekly EuroBiotech Report. We lead this week on Bayer Pharma's investment in High-Tech Gründerfonds II, a German venture fund that provides seed financing to local startups. Founders always have to give up something to access cash, but those who turned to Russia's venture capital sector for financing may have lost more than they realize. And more.
Medtronic is headed to the European market with what it says is the first implantable defibrillator cleared for full-body MRI scans, following a widespread trend toward imaging-safe implants.
Germany's Merck KGaA signed a licensing agreement with Menlo Park, CA-based Auxogyn to sell its fertility-enhancing diagnostic test in Europe and Canada with an option to extend the agreement to other countries.
Amid a continental push to make more clinical trial results available to the public, the European Medicines Agency has apparently assuaged a former foe in AbbVie, as the drugmaker dropped a lawsuit designed to block the release of data on its blockbuster Humira.
This week's edition of the EuroBiotech Report brings fresh evidence that the U.S. biotech IPO boom has landed on European shores, with other companies from the stable of Circassia-backer Imperial Innovations considering going public and InDex Pharmaceuticals preparing to test the waters in Sweden. And more.
U.K. diagnostics developer Cytox raised nearly $2.5 million in new funding to help expand work on the development of a viable Alzheimer's biomarker.
Indian drugmaker Aurobindo has completed its $41 million acquisition of 7 Actavis active pharmaceutical ingredient facilities across Western Europe.
The notion that a party drug could be repurposed into a "miracle" cure for severe, treatment-resistant depression is an almost irresistible story line in the popular press. And there's no reason why it can't be recycled using results from the same small, short-duration study design that long ago attracted some of the world's largest research organizations still engaged in researching new drugs in one of the most difficult fields in R&D.